Fellow Health has published results showing 82% compliance rates with their mail-in postvasectomy semen analysis (PVSA) kits, significantly outperforming traditional testing methods. The study, published in the Journal of Urology, demonstrates a major advancement in addressing a persistent challenge in reproductive healthcare.
The findings are particularly significant given that approximately half a million vasectomies are performed annually in the United States. While the American Urological Association recommends PVSA to confirm procedural success, traditional compliance rates typically hover between 30-50%, with even the best-performing centers achieving only 70% through intensive follow-up efforts.
The two-year prospective cohort study, which analyzed data from over 16,000 men across the U.S., showed an initial compliance rate of 69% at 18 weeks, rising to 82% by 40 weeks. These results represent the highest published compliance rates for PVSA testing to date.
“Traditional compliance efforts rely on clinics to shoulder the burden with time-consuming follow-ups or use basic mail-in options that fail to fully solve the problem,” said James F. Smith, MD, MS, Chief Medical Officer and NYS Laboratory Director of Fellow Health. “Fellow Health’s comprehensive system tackles these barriers through excellent customer support, automated reminders, and a streamlined supply chain, driving compliance rates far beyond what clinics or other mail-in systems have been able to achieve.”
The company’s solution addresses common barriers to testing compliance, including distance to testing facilities, time constraints, and lack of transportation. “PVSA compliance has been a frustrating challenge for both patients and clinics,” said Brian Hogan, CEO of Fellow Health. “This study underscores our commitment to removing barriers to PVSA compliance and improving reproductive health outcomes across the U.S. Fellow Health is setting a new standard for mail-in PVSA testing with the highest published compliance rates to date.”
